Adage Capital Partners Gp, L.L.C. Avidity Biosciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,751,944 shares of RNA stock, worth $85.6 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
2,751,944
Previous 3,079,374
10.63%
Holding current value
$85.6 Million
Previous $141 Million
43.42%
% of portfolio
0.15%
Previous 0.26%
Shares
9 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
108MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$344 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$294 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$268 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$252 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$247 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.62B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...